Literature DB >> 35813011

Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer.

Shinichiro Kashiwagi1, Yuka Asano1, Koji Takada1, Wataru Goto1, Rika Kouhashi1, Akimichi Yabumoto1, Yukie Tauchi1, Tamami Morisaki1, Kana Ogisawa1, Masatsune Shibutani2, Hiroaki Tanaka2, Masaichi Ohira1,2.   

Abstract

BACKGROUND/AIM: Tumor microenvironment (TME) assessment is considered to play an important role in the prediction of prognosis and therapeutic response following breast cancer treatment. No consensus has been reached regarding evaluation methods despite reports on the utilization of tumor-infiltrating lymphocytes (TILs) for immune TME (iTME) monitoring. Optimum timing of iTME assessment has not yet been established. PATIENTS AND METHODS: Two hundred thirty-nine patients were treated with neoadjuvant chemotherapy (NAC). During the period from diagnostic needle biopsy to NAC initiation for breast cancer, the optimal evaluation timing was examined using a receiver operating characteristic (ROC) curve analysis.
RESULTS: A significant correlation between TILs and pathological complete response (pCR) was only observed in the short-term group (≤35 days) (p=0.033). Prognostic analysis revealed that in the short-term group, patients with high TIL levels had a significantly better survival prognosis relative to those with low TIL levels (>35 days) [disease-free survival (DFS): p=0.001, overall survival (OS): p=0.021]. TILs were identified as an independent factor affecting DFS in a multivariate analysis (p=0.008, hazard ratio=0.130).
CONCLUSION: TIL assessment during NAC for breast cancer is a prognostic predictor only when performed at ≤35 days before NAC initiation. Copyright 2022, International Institute of Anticancer Research.

Entities:  

Keywords:  Tumor microenvironment; breast cancer; immune response; neoadjuvant chemotherapy; prognostic marker; tumor-infiltrating lymphocytes

Year:  2022        PMID: 35813011      PMCID: PMC9254105          DOI: 10.21873/cdp.10127

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  37 in total

1.  Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.

Authors:  Minoru Miyashita; Hironobu Sasano; Kentaro Tamaki; Monica Chan; Hisashi Hirakawa; Akihiko Suzuki; Hiroshi Tada; Go Watanabe; Noriko Nemoto; Saki Nakagawa; Takanori Ishida; Noriaki Ohuchi
Journal:  Breast Cancer Res Treat       Date:  2014-11-14       Impact factor: 4.872

2.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

Review 4.  The concept of immunological surveillance.

Authors:  F M Burnet
Journal:  Prog Exp Tumor Res       Date:  1970

5.  Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer.

Authors:  Hui Liu; Tiantuo Zhang; Jin Ye; Hongtao Li; Jing Huang; Xiaodong Li; Benquan Wu; Xubing Huang; Jinghui Hou
Journal:  Cancer Immunol Immunother       Date:  2012-03-29       Impact factor: 6.968

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 8.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 9.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 10.  Preoperative chemotherapy for women with operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.